Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant

University of Toronto

$902,700.00

Characterizing FAM72 in adaptive and innate immunity

FY 2021-22

Summary
In our previous CIHR grant, we conducted a genetic screen to identify novel genes involved in antibody production for effective immune protection. Using mouse cells, we discovered Fam72A, a gene that produces a protein causing degradation of the UNG2 mouse protein that is involved in DNA repair. By causing UNG2 degradation, FAM72A prompts the production of antibodies that bind very tightly to viruses and other pathogens. As a result, FAM72A plays an important role in ensuring that the best antibodies are produced to remove viruses and other pathogens from our bodies. Unlike mice and other mammals, including non-human primates, humans have expanded this gene family to include four closely-related genes called FAM72A-D. The function of each of these genes is not known. This proposal will explore how this relatively unknown gene family is involved in antibody production, and the role of the four closely-related FAM72A-D proteins in human biology. We hypothesize that some of these proteins are involved in degrading a related protein of UNG2 that is expressed in Herpes viruses. These viruses encode an UNG2 homologue required for viral growth and if FAM72A-D bind to and degrade viral UNG2s, they will restrict viral growth. We will also assess other functions of FAM72 proteins in human B cell biology. This proposal seeks to determine the function and role in immunity of this novel and poorly defined FAM72 gene family, contributing to the study of immunity against infectious diseases and the identification of molecular mechanisms that impact DNA repair and genetic mutation in cancer cells.
Program
Project Grant
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
451022
Name
Martin Alberto
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Immunology & Transplantation
Projecttitle
Characterizing FAM72 in adaptive and innate immunity
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$902,700
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Activation Induced Deaminase; Antibody; Class Switch Recombination; Ctlh Complex; Fam72; Immunoglobulin Genes; Maea; Somatic Hypermutation; Uracil Glycosylase Ung2
Abstract
In our previous CIHR grant, we conducted a genetic screen to identify novel genes involved in antibody production for effective immune protection. Using mouse cells, we discovered Fam72A, a gene that produces a protein causing degradation of the UNG2 mouse protein that is involved in DNA repair. By causing UNG2 degradation, FAM72A prompts the production of antibodies that bind very tightly to viruses and other pathogens. As a result, FAM72A plays an important role in ensuring that the best antibodies are produced to remove viruses and other pathogens from our bodies. Unlike mice and other mammals, including non-human primates, humans have expanded this gene family to include four closely-related genes called FAM72A-D. The function of each of these genes is not known. This proposal will explore how this relatively unknown gene family is involved in antibody production, and the role of the four closely-related FAM72A-D proteins in human biology. We hypothesize that some of these proteins are involved in degrading a related protein of UNG2 that is expressed in Herpes viruses. These viruses encode an UNG2 homologue required for viral growth and if FAM72A-D bind to and degrade viral UNG2s, they will restrict viral growth. We will also assess other functions of FAM72 proteins in human B cell biology. This proposal seeks to determine the function and role in immunity of this novel and poorly defined FAM72 gene family, contributing to the study of immunity against infectious diseases and the identification of molecular mechanisms that impact DNA repair and genetic mutation in cancer cells.
Competitiondate
202109
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Martin, Alberto
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $902,700~ $0~